請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78374
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 吳嘉文(Chia-Wen Wu) | |
dc.contributor.author | Wei-Cheng Chien | en |
dc.contributor.author | 簡瑋呈 | zh_TW |
dc.date.accessioned | 2021-07-11T14:53:42Z | - |
dc.date.available | 2022-07-31 | |
dc.date.copyright | 2020-08-04 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-07-27 | |
dc.identifier.citation | 1. Hornback, N.B., Historical aspects of hyperthermia in cancer therapy. Radiologic clinics of North America, 1989. 27(3): p. 481-488. 2. Hirsch, L.R., et al., Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proceedings of the National Academy of Sciences, 2003. 100(23): p. 13549. 3. Hazle, J.D., et al., MRI-guided thermal therapy of transplanted tumors in the canine prostate using a directional transurethral ultrasound applicator. Journal of Magnetic Resonance Imaging, 2002. 15(4): p. 409-417. 4. McCann, C., et al., Feasibility of salvage interstitial microwave thermal therapy for prostate carcinoma following failed brachytherapy: studies in a tissue equivalent phantom. Physics in Medicine and Biology, 2003. 48(8): p. 1041-1052. 5. Roemer, R.B., Engineering aspects of hyperthermia therapy. Annual Review of Biomedical Engineering, 1999. 1(1): p. 347-376. 6. Lg, L.F.F., Pathological effects of hyperthermia in normal tissues. Cancer research, 1984. 44(10 Supplement): p. 4826s-4835s. 7. Dewey, W.C., Arrhenius relationships from the molecule and cell to the clinic. International journal of hyperthermia, 1994. 10(4): p. 457-483. 8. Hettinga, J., Reduction of cisplatin resistance by hyperthermia. 1996: Rijksuniversiteit. 9. Lepock, J.R., Role of nuclear protein denaturation and aggregation in thermal radiosensitization. International journal of hyperthermia, 2004. 20(2): p. 115-130. 10. Brunetaud, J.M., et al., Non-PDT uses of lasers in oncology. Lasers in medical science, 1995. 10(1): p. 3-8. 11. Weissleder, R., A clearer vision for in vivo imaging. Nature biotechnology, 2001. 19(4): p. 316-317. 12. Gai, S., et al., Recent advances in functional nanomaterials for light–triggered cancer therapy. Nano today, 2018. 19: p. 146-187. 13. Ohulchanskyy, T.Y., et al., Phospholipid micelle-based magneto-plasmonic nanoformulation for magnetic field-directed, imaging-guided photo-induced cancer therapy. Nanomedicine: Nanotechnology, Biology and Medicine, 2013. 9(8): p. 1192-1202. 14. Bharathiraja, S., et al., Multimodal tumor-homing chitosan oligosaccharide-coated biocompatible palladium nanoparticles for photo-based imaging and therapy. Scientific reports, 2018. 8(1): p. 1-16. 15. Yang, K., et al., Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy. Nano letters, 2010. 10(9): p. 3318-3323. 16. Bian, K., et al., Peptide-directed hierarchical mineralized silver nanocages for anti-tumor photothermal therapy. ACS Sustainable Chemistry Engineering, 2018. 6(6): p. 7574-7588. 17. Hessel, C.M., et al., Copper selenide nanocrystals for photothermal therapy. Nano letters, 2011. 11(6): p. 2560-2566. 18. Wang, C., et al., Trifolium‐like platinum nanoparticle‐mediated photothermal therapy inhibits tumor growth and osteolysis in a bone metastasis model. Small, 2015. 11(17): p. 2080-2086. 19. Manivasagan, P., et al., Biocompatible chitosan oligosaccharide modified gold nanorods as highly effective photothermal agents for ablation of breast cancer cells. Polymers, 2018. 10(3): p. 232. 20. Jain, P.K., I.H. El-Sayed, and M.A. El-Sayed, Au nanoparticles target cancer. nano today, 2007. 2(1): p. 18-29. 21. Pérez-Juste, J., et al., Gold nanorods: synthesis, characterization and applications. Coordination Chemistry Reviews, 2005. 249(17-18): p. 1870-1901. 22. Smith, A.M., M.C. Mancini, and S. Nie, Bioimaging: second window for in vivo imaging. Nature nanotechnology, 2009. 4(11): p. 710. 23. Li, X., J. Qian, and S. He, Impact of the self-assembly of multilayer polyelectrolyte functionalized gold nanorods and its application to biosensing. Nanotechnology, 2008. 19(35): p. 355501. 24. Jana, N.R., L. Gearheart, and C.J. Murphy, Wet chemical synthesis of high aspect ratio cylindrical gold nanorods. The Journal of Physical Chemistry B, 2001. 105(19): p. 4065-4067. 25. Zhang, J.-J., et al., Synthesis, characterizations of silica-coated gold nanorods and its applications in electroanalysis of hemoglobin. Electrochemistry Communications, 2008. 10(3): p. 355-358. 26. Cao, J., et al., Effective surface modification of gold nanorods for localized surface plasmon resonance-based biosensors. Sensors and Actuators B: Chemical, 2012. 169: p. 360-367. 27. Gole, A. and C.J. Murphy, Polyelectrolyte-coated gold nanorods: synthesis, characterization and immobilization. Chemistry of Materials, 2005. 17(6): p. 1325-1330. 28. Chen, C.-L., et al., In situ real-time investigation of cancer cell photothermolysis mediated by excited gold nanorod surface plasmons. Biomaterials, 2010. 31(14): p. 4104-4112. 29. Liao, Y.-T., et al., Biocompatible and multifunctional gold nanorods for effective photothermal therapy of oral squamous cell carcinoma. Journal of Materials Chemistry B, 2019. 7(28): p. 4451-4460. 30. Leduskrasts, K. and E. Suna, Aggregation induced emission by pyridinium–pyridinium interactions. RSC advances, 2019. 9(1): p. 460-465. 31. Wang, J., et al., Dual targeted and pH-responsive gold nanorods with improved chemotherapy and photothermal ablation for synergistic cancer treatment. RSC advances, 2019. 9(10): p. 5270-5281. 32. Liu, J., et al., Gold nanorods coated with mesoporous silica shell as drug delivery system for remote near infrared light‐activated release and potential phototherapy. Small, 2015. 11(19): p. 2323-2332. 33. Aguilar, Z., Nanomaterials for medical applications. 2012: Newnes. 34. Deria, P., et al., Beyond post-synthesis modification: evolution of metal–organic frameworks via building block replacement. Chemical Society Reviews, 2014. 43(16): p. 5896-5912. 35. Ma, S. and H.-C. Zhou, Gas storage in porous metal–organic frameworks for clean energy applications. Chemical Communications, 2010. 46(1): p. 44-53. 36. Zhao, X., et al., Metal–organic frameworks for separation. Advanced Materials, 2018. 30(37): p. 1705189. 37. Huxford, R.C., J. Della Rocca, and W. Lin, Metal–organic frameworks as potential drug carriers. Current opinion in chemical biology, 2010. 14(2): p. 262-268. 38. Kreno, L.E., et al., Metal–organic framework materials as chemical sensors. Chemical reviews, 2012. 112(2): p. 1105-1125. 39. Chughtai, A.H., et al., Metal–organic frameworks: versatile heterogeneous catalysts for efficient catalytic organic transformations. Chemical Society Reviews, 2015. 44(19): p. 6804-6849. 40. Gaumet, M., et al., Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. European journal of pharmaceutics and biopharmaceutics, 2008. 69(1): p. 1-9. 41. He, Q., et al., An anticancer drug delivery system based on surfactant-templated mesoporous silica nanoparticles. Biomaterials, 2010. 31(12): p. 3335-3346. 42. Karthik, S., et al., Photoresponsive coumarin-tethered multifunctional magnetic nanoparticles for release of anticancer drug. ACS applied materials interfaces, 2013. 5(11): p. 5232-5238. 43. Deng, C., et al., Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: promises, progress and prospects. Nano Today, 2012. 7(5): p. 467-480. 44. Al-Jamal, W.T. and K. Kostarelos, Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Accounts of chemical research, 2011. 44(10): p. 1094-1104. 45. Fu, F., et al., Multifunctional lactobionic acid-modified dendrimers for targeted drug delivery to liver cancer cells: investigating the role played by PEG spacer. ACS applied materials interfaces, 2014. 6(18): p. 16416-16425. 46. Greenwald, R.B., et al., Effective drug delivery by PEGylated drug conjugates. Advanced drug delivery reviews, 2003. 55(2): p. 217-250. 47. Tang, S., et al., Hollow mesoporous zirconia nanocapsules for drug delivery. Advanced Functional Materials, 2010. 20(15): p. 2442-2447. 48. Shait Mohammed, M.R., et al., Prospective of nanoscale metal organic frameworks [NMOFs] for cancer therapy. Seminars in Cancer Biology, 2019. 49. Wu, M.X. and Y.W. Yang, Metal–organic framework (MOF)‐based drug/cargo delivery and cancer therapy. Advanced Materials, 2017. 29(23): p. 1606134. 50. Haydar, M.A.L., et al., Metal organic frameworks as a drug delivery system for flurbiprofen. Drug Design, Development and Therapy, 2017. 11: p. 2685. 51. Férey, G., Hybrid porous solids: past, present, future. Chemical Society Reviews, 2008. 37(1): p. 191-214. 52. Sun, C.-Y., et al., Metal-organic frameworks as potential drug delivery systems. Expert opinion on drug delivery, 2013. 10(1): p. 89-101. 53. Mizutani, M., et al., An infinite chiral single-helical structure formed in Cu (II)-L-/D-glutamic acid system. Inorganica chimica acta, 1998. 283(1): p. 105-110. 54. Schally, A.V. and A. Nagy, Chemotherapy targeted to cancers through tumoral hormone receptors. Trends in Endocrinology Metabolism, 2004. 15(7): p. 300-310. 55. Danhier, F., O. Feron, and V. Préat, To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of controlled release, 2010. 148(2): p. 135-146. 56. Torchilin, V.P., Drug targeting. European Journal of Pharmaceutical Sciences, 2000. 11: p. S81-S91. 57. Xie, J., et al., Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials, 2019: p. 119491. 58. Murray, P.J. and T.A. Wynn, Protective and pathogenic functions of macrophage subsets. Nature reviews immunology, 2011. 11(11): p. 723-737. 59. Chanmee, T., et al., Tumor-associated macrophages as major players in the tumor microenvironment. Cancers, 2014. 6(3): p. 1670-1690. 60. Lewis, J.S., et al., Expression of vascular endothelial growth factor by macrophages is up‐regulated in poorly vascularized areas of breast carcinomas. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, 2000. 192(2): p. 150-158. 61. Grimshaw, M.J., J.L. Wilson, and F.R. Balkwill, Endothelin‐2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. European journal of immunology, 2002. 32(9): p. 2393-2400. 62. Matschurat, S., et al., Regulation of EMAP II by hypoxia. The American journal of pathology, 2003. 162(1): p. 93-103. 63. Richards, D.M., J. Hettinger, and M. Feuerer, Monocytes and macrophages in cancer: development and functions. Cancer Microenviron, 2013. 6(2): p. 179-91. 64. Qian, B.Z., et al., CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature, 2011. 475(7355): p. 222-5. 65. Negus, R.P., et al., The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest, 1995. 95(5): p. 2391-6. 66. Arenberg, D.A., et al., Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol Immunother, 2000. 49(2): p. 63-70. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78374 | - |
dc.description.abstract | 腫瘤內的缺氧區因為血管缺乏與氧氣含量低導致癌症治療的功效不足進是造成癌症容易復發的原因之一。巨噬細胞具有突破血管屏障抵達缺氧區的能力,藉由巨噬細胞傳遞藥物以標靶腫瘤是一相當具有潛力的傳遞方式 我成功將單核球趨化蛋白-1(MCP-1)與有機金屬框架(MIL-100)修飾於光熱材料奈米金棒(GNR)上,以吸引巨噬細胞的吞噬與材料的生物相容性同時具有標靶腫瘤的能力。從穿透式電子顯微鏡(TEM)、紫外光可見光光譜儀(UV-Vis)與傅立葉轉換紅外光(FTIR)等結果證實我成功製備出MCP-1/GNR@MIL-100,從生物毒性結果看出經由MIL-100修飾後的生物毒性大幅改善。藉由細胞遷移實驗與光學顯微鏡的觀察可以看出經由MCP-1的修飾可以提高巨噬細胞的吸引與吞噬,同時巨噬細胞在攜帶材料後也具有標靶腫瘤的能力。在經過光熱治療後癌細胞的存活率僅剩20%,這些都證實此材料具有很好的潛力應用在生物體內進行癌症治療。 | zh_TW |
dc.description.abstract | The insufficient blood vessel and oxygen concentration in hypoxia induce the low efficiency of anti-cancer therapeutics and easy relapse. Macrophage has the ability to cross the blood-vessel barriers to reach the hypoxic region of tumors, so target the tumor by macrophage delivery has been a good potential in tumor targeting. In this work, I successfully modify monocyte chemoattractant protein-1 (MCP-1) and iron-based metal-organic framework (MIL-100) on phototheraml agent, gold nanorods (GNR) (i.e. MCP-1/GNR@MIL-100), in order to increase cellular uptake and biocompatibility. TEM, UV-Vis, and FTIR show successfully synthesis of MCP-1/GNR@MIL-100, and the biocompatibility was improved after MIL-100 modification. Transwell assay show macrophage attractant and material uptake show 1.5 time increase after MCP-1 functionalization and also indicate the macrophage have tumor targeting ability. The in vitro photothermal therapy result show the cell viability decreased to 20%, it all show the materials have good potential in cancer therapy in in vivo experiment. | en |
dc.description.provenance | Made available in DSpace on 2021-07-11T14:53:42Z (GMT). No. of bitstreams: 1 U0001-1607202014301300.pdf: 3272094 bytes, checksum: c228b321d3d8bf914aaffae1fa330977 (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | Abstract i 摘要 ii List of Figures v List of Tables vii 1. Introduction 1 1.1. Thermal therapy 1 1.2. Photothermal therapy 2 1.3. Gold nanorods (GNR) 4 1.4. Self-assembled monolayers (SAMs) 6 1.5. Metal-Organic Frameworks (MOFs) 7 1.6. MOFs applied in drug delivery system (DDS) 8 1.7. Tumor targeting 11 1.8. Passive targeting 12 1.9. Active targeting 13 1.10. Mechanisms of monocyte/macrophage recruitment 14 2. Objectives 17 3. Experimental 18 3.1. Chemicals and materials 18 3.2. Equipment 20 3.3. Synthesis of Gold nanorods (GNRs) 22 3.4. Ligand exchange of CTAB-stabilized GNR with MUA 22 3.5. Fabrication of core-shell GNR@MIL-100(Fe) 23 3.6. Functionalization of GNR@MIL-100 (Fe) with MCP-1 23 3.7. Characterization 24 3.7.1. High Resolution Transmission Electron Microscope (HR-TEM) 24 3.7.2. TEM-Energy Dispersive Spectroscopy (EDS) 25 3.7.3. X-ray Diffractometer (XRD) 25 3.7.4. Ultraviolet-Visible Spectroscopy (UV-Vis) 26 3.7.5. Fourier Transform Infrared Spectrometer (FTIR) 26 3.7.6. Dynamic Light Scattering Zeta Potential Analyzer 26 3.7.7. Photothermal Activity Analysis 27 3.7.8. BCA Protein Assay 28 3.7.9. Cell Culture 31 3.7.10. MTT Assay 32 3.7.11. Migration rate assay 34 3.7.12. Cellular uptake of MCP-1/GNR@MIL-100 (Fe) 37 3.7.13. In vitro photothermal therapy 38 3.7.14. Statistical analysis 39 4. Results and Discussion 40 4.1. Material characterizations 40 4.1.1. Synthesis of gold nanorods(GNRs) 40 4.1.2. Ligand exchange of CTAB-stabilized GNR with MUA 41 4.1.3. Fabrication of core-shell GNR@MIL-100(Fe) 43 4.1.4. Functionalization of GNR@MIL-100(Fe) with MCP-1 45 4.1.5. Photothermal activity 46 4.2. In vitro experiments 49 4.2.1. Cell viability 49 4.2.2. Cell migration 50 4.2.3. In vitro photothermal therapy 54 5. Conclusion 56 6. Future prospect 57 7. Reference 58 Appendix 63 A.1 Crystallinity of GNR@MIL-100 63 A.2 UV-Vis spectrum of GNR@MUA and GNR@MIL-100 63 A.3 BCA assay calibration curve 64 A.4 (a)Surface (b)Intracellular secretion of CCL2 by different glioblastoma (Done by Ph. D. Jung-Tung Hung, Chang Gung Memorial Hospital) 65 | |
dc.language.iso | en | |
dc.title | 製備MCP-1功能化之含奈米金棒有機金屬框架(MCP-1-GNR@MIL-100)利用免疫細胞傳遞並標靶腫瘤進行光熱治療 | zh_TW |
dc.title | MCP-1 Functionalized, Gold Nanorods@Metal-Organic Frameworks (MIL-100(Fe)) Core-Shell Nanoparticles for Immune Cell Drug Delivery and Photothermal Therapy | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳韻晶(Yun-Ching Chen),盧郁仁(Yu-Jen Lu),胡哲銘(Che-Ming Hu),李佳洪(Chia-Hung Lee) | |
dc.subject.keyword | 奈米金棒,有機金屬框架,光熱治療,單核球趨化蛋白-1 (MCP-1), | zh_TW |
dc.subject.keyword | Gold nanorods,MIL-100,photothermal therapy,monocyte chemoattractant protein-1 (MCP-1), | en |
dc.relation.page | 66 | |
dc.identifier.doi | 10.6342/NTU202001571 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-07-27 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 化學工程學研究所 | zh_TW |
顯示於系所單位: | 化學工程學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1607202014301300.pdf 目前未授權公開取用 | 3.2 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。